U.S. Markets open in 2 hrs 5 mins

CLASS ACTION UPDATE for ZGNX, APYX and SCOR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / June 6, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.

Zogenix, Inc. (ZGNX)

Class Period: February 6, 2019 - April 8, 2019
Lead Plaintiff Deadline : June 11, 2019
Join the action: https://www.zlk.com/pslra-1/zogenix-inc-loss-form?prid=1849&wire=1

Allegations: Zogenix, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Zogenix's NDA for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset; (ii) consequently, Zogenix's NDA for FINTEPLA was unlikely to gain FDA approval; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more about the Zogenix, Inc. class action contact jlevi@levikorsinsky.com.

Apyx Medical Corporation (APYX)

Class Period: August 1, 2018 - April 1, 2019
Lead Plaintiff Deadline : June 17, 2019
Join the action: https://www.zlk.com/pslra-1/apyx-medical-corporation-loss-form?prid=1849&wire=1

Allegations: Apyx Medical Corporation made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) the clinical study on the use of J-Plasma for dermal resurfacing had not met its primary efficacy endpoint; (2) as a result, the clinical study did not support the Company's application for regulatory clearance; (3) as a result, the Company was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

To learn more about the Apyx Medical Corporation class action contact jlevi@levikorsinsky.com.

comScore, Inc. (SCOR)

Class Period: November 8, 2018 - March 29, 2019
Lead Plaintiff Deadline : June 10, 2019
Join the action: https://www.zlk.com/pslra-1/comscore-inc-loss-form?prid=1849&wire=1

Allegations: During the class period, comScore, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) that the Company was experiencing difficulties implementing its business strategy; (2) that, as a result, the Company's financial results would be materially impacted; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more about the comScore, Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/548015/CLASS-ACTION-UPDATE-for-ZGNX-APYX-and-SCOR-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders